Cart is empty Pfizer said Thursday it completed a $43 billion takeover of cancer-focused biotech company Seagen that the pharma giant said would enable it to double its oncology platform.
Pfizer said Thursday it completed a $43 billion takeover of cancer-focused biotech company Seagen that the pharma giant said would enable it to double its oncology platform.
Leave A Comment